HCV / Hepatitis

Emerging evidence suggests that confirming hepatitis C cure at 4 weeks post-treatment could improve patient engagement and reduce barriers to care without compromising accuracy. Meghan D. Morris, PhD, MPH, offers insights around her study on this subject.

This week, read about AI and antibiotic development, an innovative hepatitis C program to get postpartum mothers tested and treated sooner, on World Liver Day a nurse talks about her personal story and how she advocate for better education around this vital organ, and more.

In honor of World Liver Day 2026, a nurse shares the heartbreaking story of her son’s fatal liver disease and her lifelong mission to educate the public about the vital, often overlooked role of liver health.

A nurse’s decades-long advocacy highlights how personal loss and gaps in public education have shaped ongoing challenges in hepatitis B vaccination and liver disease awareness.

New research from UC San Francisco (UCSF) suggests hepatitis C cure may be reliably confirmed as early as four weeks after treatment, potentially improving care access for underserved populations.

The rate of HBV vaccination of newborns in the US has declined by over 10% in the past 2 years, reversing decades of increasing coverage.

New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analogue AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label options, supporting plans to advance the candidate into phase 1 clinical development in 2026.

Here are some therapeutics and a vaccine that will be reporting data, starting a trial, or filing their data to regulatory agencies in order to seek approval this year.

The recent CDC ACIP meetings and subsequent actions show a path for which the current Health and Human Services department wants to roll back access to vaccines for this virus and other vaccines.

Agreement supports commercialization and reimbursement efforts for tobevibart plus elebsiran as the ECLIPSE clinical program advances, including completion of enrollment for the ECLIPSE 3 trial.

The single-source award will fund a large randomized trial evaluating mortality, morbidity, and developmental outcomes following the hepatitis B birth dose, amid ongoing debate over non-specific vaccine effects.

This new recommendation relates to infants born to women who test negative for hepatitis B. This is a departure from the federal agency’s previous recommendation and comes on the heels of the ACIP’s recent meeting.

This week, read our coverage on the CDC ACIP meetings on the hepatitis B virus (HBV) vaccine, modeling data on the potential consequences of HBV infections, liver cancer, and mortality when delaying the birth dose to 2 months, our latest podcast, and more.

Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose is administered no earlier than 2 months of age.”

Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.

A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.

New modeling and clinical data presented by Atea Pharmaceuticals suggest that its fixed-dose combination of bemnifosbuvir and ruzasvir could offer a potent, short-duration, best-in-class treatment option for hepatitis.

A mother recounts her newborn son's fatal battle with cirrhosis reminding people of the importance of health and education about this vital organ.

Primary completion is expected in Q4 2026 with topline results in Q1 2027, while ECLIPSE 2 and 3 continue enrolling to support potential US and EU submissions.

Immunocore’s first-in-human study of its bispecific, IMC-I109V, demonstrated early antiviral activity and a favorable safety profile, supporting continued development of the TCR bispecific candidate as a potential functional cure for chronic hepatitis B.

In Vir Biotechnology’s phase 2 Solstice study, 66% of participants with chronic hepatitis delta (CHD) receiving a monthly dose of combination tobevibart and elebsiran achieved undetectable hepatitis delta virus (HDV) RNA at Week 48.

The XpertHCV test from Cepheid enables rapid, point-of-care detection of hepatitis C infection in under an hour—helping to expand access to care and reduces follow-up loss.

Sustained HIV/syphilis elimination of mother-to-child transmission (EMTCT) since 2019 and new hepatitis B validation reflect high antenatal screening, >95% HBV birth-dose coverage, and integrated maternal–child health services.

This week, learn about the Center for Discovery and Innovation's research around vaccines and the next generation of rifamycins, as well as results from a Cefiderocol study looking at healthcare-associated Gram-negative bloodstream infections and more.

NIH funds an effort to adapt an electrochemical biosensor for same-visit detection and viral-load quantification at the point of care.